- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07319247
Terapia laserowa i trening mięśni dna miednicy w przypadku wysiłkowego nietrzymania moczu
Wpływ wysokoczęstotliwościowej terapii laserowej i treningu mięśni dna miednicy u kobiet z wysiłkowym nietrzymaniem moczu: placebo-randomizowane badanie kontrolowane
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Konya
-
Meram, Konya, Turcja (Türkiye), (507) 534-6142
- Physical Therapy Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Opis
Kryteria włączenia:
- Kobiety w wieku 18-65 lat,
- Kobiety będące wolontariuszkami i zaangażowane w pracę,
- Kobiety z rozpoznanym wysiłkowym nietrzymaniem moczu,
Kryteria wykluczenia:
- Ciaża,
- Przebyta operacja w obszarze leczenia w ciągu ostatnich 12 miesięcy,
- Aktywna infekcja narządów płciowych,
- Obecność nowotworu złośliwego,
- Stosowanie steroidów systemowych w ciągu ostatnich 3 miesięcy,
- Stosowanie lubrykantu dopochwowego w ciągu ostatnich 7 dni,
- Nawracające zakażenia dróg moczowych lub opryszczka narządów płciowych,
- Wynik POP-Q 3 lub wyższy
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Komparator placebo: Plasebo Laser
This group will only receive placebo laser treatment.
The ND: YAG laser system was configured identically, except for the addition of a metal shielding plate to the hand tool to block energy, which had no therapeutic effect, during treatment.
The laser device will be aimed at 6 points in the perineal area .
Assessments will be conducted twice, baseline and post treatment (at 12 weeks).
|
This group will only receive placebo laser treatment.
The ND: YAG laser system was configured identically, except for the addition of a metal shielding plate to the hand tool to block energy, which had no therapeutic effect, during treatment.
The laser device will be aimed at 6 points in the perineal area .
Assessments will be conducted twice, baseline and post treatment (at 12 weeks).
|
|
Aktywny komparator: PFME
In this training, patients are taught pelvic floor exercises, which involve slow and fast muscle contractions that train both Type 1 and Type 2 muscle fibers, using vaginal palpation.
During fast contractions, patients are asked to quickly contract and relax their pelvic floor muscles.
The image of "turning the faucet off and on" is used to help patients better understand this exercise.
During slow contractions, patients are asked to slowly tighten their pelvic floor muscles, hold them for 10 seconds, and then slowly relax them.
One set of pelvic floor muscle exercises consists of 10 fast contractions and 10 slow contractions.
According to this program, pelvic floor exercises are performed in weeks 1-2, 2 sets in weeks 3-4, 4 sets in weeks 5-6, 8 sets in weeks 7-8, and 10 sets in weeks 8-12.
Assessments will be conducted twice, baseline and post treatment (at 12 week).
|
In this training, patients are taught pelvic floor exercises, which involve slow and fast muscle contractions that train both Type 1 and Type 2 muscle fibers, using vaginal palpation.
During fast contractions, patients are asked to quickly contract and relax their pelvic floor muscles.
The image of "turning the faucet off and on" is used to help patients better understand this exercise.
During slow contractions, patients are asked to slowly tighten their pelvic floor muscles, hold them for 10 seconds, and then slowly relax them.
One set of pelvic floor muscle exercises consists of 10 fast contractions and 10 slow contractions.
According to this program, pelvic floor exercises are performed in weeks 1-2, 2 sets in weeks 3-4, 4 sets in weeks 5-6, 8 sets in weeks 7-8, and 10 sets in weeks 8-12.
Assessments will be conducted twice, baseline and post treatment (at 12 week).
|
|
Eksperymentalny: PFME and Laser Therapy
PFMT, patients are taught pelvic floor exercises, which involve slow and fast muscle contractions that train both Type 1 and Type 2 muscle fibers, using vaginal palpation.
During fast contractions, patients are asked to quickly contract and relax their pelvic floor muscles.
The image of "turning the faucet off and on" is used to help patients better understand this exercise.
During slow contractions, patients are asked to slowly tighten their pelvic floor muscles, hold them for 10 seconds, and then slowly relax them.
One set of pelvic floor muscle exercises consists of 10 fast contractions and 10 slow contractions.
Assessments will be conducted twice, baseline and post treatment (at 12 weeks).
Laser was also applied to this group.
Laser application is applied to 6 points in the perineal area.
Continue and biostimulatory mode, intensity 6W, energy density 120J/cm2.
Application time is 2 minutes for each point, and a total of 6 sessions are applied 3 time.
|
PFMT, patients are taught pelvic floor exercises, which involve slow and fast muscle contractions that train both Type 1 and Type 2 muscle fibers, using vaginal palpation. During fast contractions, patients are asked to quickly contract and relax their pelvic floor muscles. The image of "turning the faucet off and on" is used to help patients better understand this exercise. During slow contractions, patients are asked to slowly tighten their pelvic floor muscles, hold them for 10 seconds, and then slowly relax them. One set of pelvic floor muscle exercises consists of 10 fast contractions and 10 slow contractions. According to this program, pelvic floor exercises are performed in weeks 1-2, in weeks 3-4, in weeks 5-6, in weeks 8-12, and in weeks 12. Laser application is applied to 6 points in the perineal area. Continue and biostimulatory mode, intensity 6W, energy density 120J/cm2. Application time is 2 minutes for each point, and a total of 6 sessions are applied 3 time |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Urinary incontinence severity
Ramy czasowe: baseline, post treatment (at 12 week)
|
The Incontinence Severity Index (ISI): This is a two-question questionnaire that helps calculate the severity of urinary incontinence in patients.
It categorizes incontinence severity into three groups: mild, moderate, and severe.
It is a useful method for monitoring and assessing incontinence severity.
|
baseline, post treatment (at 12 week)
|
|
The impact of urinary incontinence on quality of life
Ramy czasowe: baseline, post treatment (at 12 week)
|
The Incontinence Quality of Life Scale (I-QOL) will be used to determine the impact of urinary incontinence on quality of life in women.
It consists of questions under three headings: behavioral, psychological, and social impact.
The questions will be asked of the participants and recorded.
|
baseline, post treatment (at 12 week)
|
|
pelvic floor dysfuntion severity
Ramy czasowe: baseline, post treatment (at 12 week)
|
The Global Pelvic Floor Impact Questionnaire (GPTRA): This questionnaire consists of nine questions addressing pelvic floor dysfunction.
A higher total score indicates a greater degree of symptoms.
Participants were asked questions and recorded.
|
baseline, post treatment (at 12 week)
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Sexually Dysfunction
Ramy czasowe: baseline, post treatment (at 12 week)
|
The Female Sexual Function Index (FSFI): It consists of nineteen separate questions. It has six subscales: desire, arousal, lubrication, orgasm, general satisfaction, and pain. Questions 3-14 and 15-19 are scored on a 6-point Likert-type scale (0-5), while the remaining questions are scored on a 5-point Likert-type scale (1-5). The scale, which can be applied to those who have had sexual intercourse within the last month, is scored negatively, with higher scores interpreted as indicating no or low sexual dysfunction. The highest possible score is 36.0, and the lowest is 2.0. The cut-off score is 26.55. Scores of 26.55 and below are considered to indicate sexual dysfunction. |
baseline, post treatment (at 12 week)
|
|
pelvic floor muscle function
Ramy czasowe: baseline, post treatment (at 12 week)
|
Pelvic floor muscle function will be assessed with EMG biofeedback.
|
baseline, post treatment (at 12 week)
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Choroby układu moczowo-płciowego u mężczyzn
- Choroby Urologiczne
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Zaburzenia oddawania moczu
- Objawy dolnych dróg moczowych
- Manifestacje urologiczne
- Stany patologiczne, oznaki i objawy
- Objawy i symptomy
- Niemożność utrzymania moczu
- Nietrzymanie moczu, stres
- Lecznictwo
- Procedury chirurgiczne, operacyjny
- Techniki ablacji
- Terapia laserowa
- estry metylowej pentalenolaktonu F
Inne numery identyfikacyjne badania
- hlaser
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .